Merck Q3 profit beats estimates

Pharma giant Merck (MRK) swung to a profit in the third quarter from a loss last year, driven by lower costs and expenses. While R&D expenses fell 53%, materials and production costs witnessed a hike of 9%. The bottom line came in above analysts’ expectations, while the top line missed consensus estimates. Net income was … Continue reading Merck Q3 profit beats estimates